156897-06-2 | Licofelone

Packsize	Purity	Availability	Price	Discounted Price
1mg	≥98%	in stock	$71.00	$50.00
5mg	≥98%	in stock	$160.00	$112.00
25mg	≥98%	in stock	$543.00	$380.00
50mg	≥98%	in stock	$936.00	$655.00
100mg	≥98%	in stock	$1,644.00	$1,151.00
500mg	98% by HPLC	in stock	$6,653.00	$4,657.00
1000mg	98% by HPLC	in stock	$10,613.00	$7,429.00

Description

• Catalog Number: AA78917
• Chemical Name: Licofelone
• CAS Number: 156897-06-2
• Molecular Formula: C23H22ClNO2
• Molecular Weight: 379.8793
• MDL Number: MFCD00929900
• SMILES: OC(=O)Cc1c(c2ccc(cc2)Cl)c(c2n1CC(C2)(C)C)c1ccccc1

Computed Properties

• Complexity: 537
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 27
• Hydrogen Bond Acceptor Count: 2
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• XLogP3: 5.2

Literature

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Licofelone inhibits interleukin-18-induced pro-inflammatory cytokine release and cellular proliferation in human mesangial cells.

  Basic & clinical pharmacology & toxicology 20120901

• The decrease of cell membrane fluidity by the non-steroidal anti-inflammatory drug Licofelone inhibits epidermal growth factor receptor signalling and triggers apoptosis in HCA-7 colon cancer cells.

  Cancer letters 20120828

• Ciliary beating is depressed in nasal cilia from chronic obstructive pulmonary disease subjects.

  Respiratory medicine 20120801

• Efficient synthesis and 5-LOX/COX-inhibitory activity of some 3-hydroxybenzo[b]thiophene-2-carboxylic acid derivatives.

  Bioorganic & medicinal chemistry letters 20120801

• Dynamic modeling of human 5-lipoxygenase-inhibitor interactions helps to discover novel inhibitors.

  Journal of medicinal chemistry 20120322

• Targeting bone alleviates osteoarthritis in osteopenic mice and modulates cartilage catabolism.

  PloS one 20120101

• Prostaglandins in cancer cell adhesion, migration, and invasion.

  International journal of cell biology 20120101

• Anti-inflammatory drugs and prediction of new structures by comparative analysis.

  Anti-inflammatory & anti-allergy agents in medicinal chemistry 20120101

• Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention.

  Cancer prevention research (Philadelphia, Pa.) 20111201

• Role of LOX/COX pathways in 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats: protective effect of licofelone.

  British journal of pharmacology 20110901

• Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation.

  Annals of the rheumatic diseases 20110801

• Chemopreventive efficacy and mechanism of licofelone in a mouse lung tumor model via aspiration.

  Cancer prevention research (Philadelphia, Pa.) 20110801

• Licofelone-nitric oxide donors as anticancer agents.

  Archiv der Pharmazie 20110801

• Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI.

  Annals of the rheumatic diseases 20110601

• Antibody-mediated 'universal' osteoclast targeting platform using calcitonin as a model drug.

  Pharmaceutical research 20110501

• Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase.

  Journal of medicinal chemistry 20110428

• Licofelone attenuates quinolinic acid induced Huntington like symptoms: possible behavioral, biochemical and cellular alterations.

  Progress in neuro-psychopharmacology & biological psychiatry 20110330

• Investigations on cytotoxicity and anti-inflammatory potency of licofelone derivatives.

  European journal of medicinal chemistry 20110301

• [Cyclooxygenases inhibitors and other compounds with antiinflammatory potential in osteoarthrosis--part I].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20110101

• Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model.

  Arthritis research & therapy 20110101

• The implications of relationships between human diseases and metabolic subpathways.

  PloS one 20110101

• Molecular changes in articular cartilage and subchondral bone in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis.

  BMC musculoskeletal disorders 20110101

• Sequential alterations in catabolic and anabolic gene expression parallel pathological changes during progression of monoiodoacetate-induced arthritis.

  PloS one 20110101

• Quantitative cartilage imaging in knee osteoarthritis.

  Arthritis 20110101

• Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis.

  Annals of the rheumatic diseases 20101201

• Relationship between bone marrow lesions, cartilage loss and pain in knee osteoarthritis: results from a randomised controlled clinical trial using MRI.

  Annals of the rheumatic diseases 20101201

• Licofelone attenuates MPTP-induced neuronal toxicity: behavioral, biochemical and cellular evidence.

  Inflammopharmacology 20101001

• Anti-atherogenic effect of BHB-TZD having inhibitory activities on cyclooxygenase and 5-lipoxygenase in hyperlipidemic mice.

  Atherosclerosis 20100901

• Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase.

  European journal of medicinal chemistry 20100201

• Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.

  Bioorganic & medicinal chemistry letters 20100201

• Regulation of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase-activating protein/5-lipoxygenase by 4-hydroxynonenal in human osteoarthritic chondrocytes.

  Arthritis research & therapy 20100101

• High mobility group box 1 potentiates the pro-inflammatory effects of interleukin-1β in osteoarthritic synoviocytes.

  Arthritis research & therapy 20100101

• Oestrogen is important for maintenance of cartilage and subchondral bone in a murine model of knee osteoarthritis.

  Arthritis research & therapy 20100101

• Upregulation of MMP-13 and TIMP-1 expression in response to mechanical strain in MC3T3-E1 osteoblastic cells.

  BMC research notes 20100101

• Investigational pharmacology for low back pain.

  Journal of pain research 20100101

• 5-lipoxygenase: underappreciated role of a pro-inflammatory enzyme in tumorigenesis.

  Frontiers in pharmacology 20100101

• Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI.

  Annals of the rheumatic diseases 20090601

• Systematic review of the management of canine osteoarthritis.

  The Veterinary record 20090404

• Protective effects of total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13.

  Arthritis research & therapy 20090101

• An exploration of the ability of tepoxalin to ameliorate the degradation of articular cartilage in a canine in vitro model.

  BMC veterinary research 20090101

• Treatment with ephrin B2 positively impacts the abnormal metabolism of human osteoarthritic chondrocytes.

  Arthritis research & therapy 20090101

• The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer.

  Biologics : targets & therapy 20081201

• Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1.

  The Journal of pharmacology and experimental therapeutics 20080901

• In vitro metabolism of 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and -2 and 5-lipoxygenase.

  Drug metabolism and disposition: the biological fate of chemicals 20080501

• The dual inhibitor of lipoxygenase and cyclooxygenase ML3000 decreases the expression of CXCR3 ligands.

  Annals of the rheumatic diseases 20080401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080301

• Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade.

  Carcinogenesis 20080201

• Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) selectivity of COX inhibitors.

  Prostaglandins, leukotrienes, and essential fatty acids 20080201

• A role for subchondral bone changes in the process of osteoarthritis; a micro-CT study of two canine models.

  BMC musculoskeletal disorders 20080101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080101

• Licofelone: the answer to unmet needs in osteoarthritis therapy?

  Current rheumatology reports 20080101

• Is collagenase-3 (MMP-13) expression in chondrosarcoma of the jaws a true marker for tumor aggressiveness?

  Diagnostic pathology 20080101

• Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodelling.

  Arthritis research & therapy 20080101

• Finding multiple target optimal intervention in disease-related molecular network.

  Molecular systems biology 20080101

• Analysis of the precision and sensitivity to change of different approaches to assess cartilage loss by quantitative MRI in a longitudinal multicentre clinical trial in patients with knee osteoarthritis.

  Arthritis research & therapy 20080101

• Combination Therapy of PPARgamma Ligands and Inhibitors of Arachidonic Acid in Lung Cancer.

  PPAR research 20080101

• Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor.

  The Journal of pharmacology and experimental therapeutics 20071201

• The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products.

  British journal of pharmacology 20071001

• Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond.

  Acta bio-medica : Atenei Parmensis 20070801

• Efficacy of licofelone in dogs with clinical osteoarthritis.

  The Veterinary record 20070428

• Dynamic simulations on the arachidonic acid metabolic network.

  PLoS computational biology 20070301

• Activity and potential role of licofelone in the management of osteoarthritis.

  Clinical interventions in aging 20070301

• Arthritis clinical trial results revealed.

  JAMA 20070103

• Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis.

  The Journal of pharmacology and experimental therapeutics 20070101

• Licofelone--a novel analgesic and anti-inflammatory agent.

  Current topics in medicinal chemistry 20070101

• Selection of reliable reference genes for qPCR studies on chondroprotective action.

  BMC molecular biology 20070101

• Extracellular localization of galectin-3 has a deleterious role in joint tissues.

  Arthritis research & therapy 20070101

• Anticancer effects of licofelone (ML-3000) in prostate cancer cells.

  Anticancer research 20070101

• DMOAD developments: present and future.

  Bulletin of the NYU hospital for joint diseases 20070101

• Activation of proteinase-activated receptor 2 in human osteoarthritic cartilage upregulates catabolic and proinflammatory pathways capable of inducing cartilage degradation: a basic science study.

  Arthritis research & therapy 20070101

• Effects on primary haemostasis of an anti-inflammatory agent with 5-lipoxygenase and cyclooxygenase inhibitory activity.

  Journal of cardiovascular medicine (Hagerstown, Md.) 20061201

• The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit.

  European journal of pharmacology 20060928

• Licofelone reduces progression of structural changes in a canine model of osteoarthritis under curative conditions: effect on protease expression and activity.

  The Journal of rheumatology 20060601

• Anti-inflammatory effect of licofelone against various inflammatory challenges.

  Fundamental & clinical pharmacology 20060201

• Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow.

  Arthritis research & therapy 20060101

• Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow.

  Biochemical pharmacology 20050701

• The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway.

  Annals of the rheumatic diseases 20050601

• Eicosanoids, osteoarthritis, and crystal deposition diseases.

  Current opinion in rheumatology 20050501

• Dual inhibition of cyclo-oxygenases and 5-lipoxygenase: a novel therapeutic approach to inflammation?

  Joint, bone, spine : revue du rhumatisme 20050501

• Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin 1beta synthesis.

  The Journal of rheumatology 20050401

• Effect of licofelone against NSAIDs-induced gastrointestinal ulceration and inflammation.

  Indian journal of experimental biology 20050301

• Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs.

  Journal of veterinary pharmacology and therapeutics 20050201

• Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: the example of licofelone.

  Drugs & aging 20050101

• Effect of licofelone against mechanical hyperalgesia and cold allodynia in the rat model of incisional pain.

  Pharmacological reports : PR 20050101

• The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases.

  Arthritis research & therapy 20050101

• Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B(4) in osteoarthritic chondrocytes: role of transforming growth factor beta and eicosanoids.

  Arthritis and rheumatism 20041201

• Pain and osteoarthritis: new drugs and mechanisms.

  Current opinion in rheumatology 20040901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040901

• The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial.

  The American journal of gastroenterology 20040401

• Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.

  European journal of pharmacology 20040319

• The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K.

  Bone 20040301

• Is licofelone, a dual inhibitor of cyclo-oxygenase and 5-lipoxygenase, a promising alternative in anti-inflammatory therapy?

  Fundamental & clinical pharmacology 20040201

• Osteoarthritis therapy--are there still unmet needs?

  Rheumatology (Oxford, England) 20040201

• Safety of anti-inflammatory treatment--new ways of thinking.

  Rheumatology (Oxford, England) 20040201

• Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis.

  Rheumatology (Oxford, England) 20040201

• Treatment with licofelone prevents abnormal subchondral bone cell metabolism in experimental dog osteoarthritis.

  Annals of the rheumatic diseases 20040101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040101

• Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000.

  BMC gastroenterology 20040101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20031201

• Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin.

  British journal of pharmacology 20030801

• Licofelone (Merckle).

  IDrugs : the investigational drugs journal 20030801

• International Conference on Inflammopharmacology -- VIII Side-Effects of Anti-inflammatory Drugs Symposium.

  Expert opinion on investigational drugs 20030701

• The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy.

  Prostaglandins & other lipid mediators 20030701

• Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20030601

• Anti arthritic drugs--SMi conference: dual inhibitors. 28-29 April 2003, London, UK.

  IDrugs : the investigational drugs journal 20030601

• COX-LOX inhibition: current evidence for an emerging new therapy.

  International journal of clinical practice 20030501

• Licofelone, a dual lipoxygenase-cyclooxygenase inhibitor, downregulates polymorphonuclear leukocyte and platelet function.

  European journal of pharmacology 20021018

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021001

• Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition.

  Arthritis and rheumatism 20020701

• Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors.

  The Journal of rheumatology 20020701

• Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with Cox/5-LOX inhibitory activity.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20020301

• The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20020301

• In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1beta synthesis.

  Arthritis and rheumatism 20011001

• [Double blockade should protect the stomach. New approach to rheumatism].

  MMW Fortschritte der Medizin 20010920

• Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis.

  The Journal of rheumatology 20010901